围术期非诺贝特对腹主动脉瘤病理影响的随机对照试验:FAME试验结果
最终40例随访至手术(非诺贝特组21例、安慰剂组19例),非诺贝特组血清甘油三酯显著下降,但主要结局(AAA组织OPN浓度、血清OPN浓度、AAA巨噬细胞数量)及探索性结局组间均无差异。结论:短期非诺贝特145 mg/日未降低大AAA患者的OPN浓度或主动脉巨噬细胞密度。
要点
- 短期非诺贝特145 mg/日未降低AAA组织及血清OPN浓度。
- 未观察到主动脉巨噬细胞密度或其他探索性结局的组间差异。
- 非诺贝特组血清甘油三酯显著下降,提示药物依从性或药效可测。
核心结论
- 在大AAA患者中,短期(至少术前两周)非诺贝特145 mg/日未降低OPN浓度或主动脉巨噬细胞密度。
研究设计与样本
- 随机双盲平行对照试验,纳入年龄≥60岁、无症状AAA瘤径≥50 mm且拟行开放AAA修复的男女患者。
- 非诺贝特145 mg/日或匹配安慰剂,至少术前两周给药;招募时和术前采血,术中取AAA活检。
- 主要结局为AAA OPN浓度、血清OPN浓度和AAA巨噬细胞数量;探索性结局包括其他既往与AAA相关蛋白的循环及主动脉浓度。
- 单时间点结局用逻辑回归比较,纵向结局用线性混合效应模型比较。
主要发现
- 非诺贝特组血清甘油三酯从招募至术前显著下降。
- 主要结局和探索性结局均未观察到组间差异。
关键数值与推荐
- 非诺贝特剂量145 mg/日,至少术前两周给药。
- 纳入标准:年龄≥60岁、无症状AAA瘤径≥50 mm、拟行开放AAA修复。
临床怎么用
- 不支持以短期非诺贝特145 mg/日来降低大AAA患者OPN浓度或主动脉巨噬细胞密度。
- 围术期使用非诺贝特可降低血清甘油三酯,但本研究未显示对AAA病理学指标获益。
局限性
- 样本量小(最终40例随访至手术)。
- 干预时间短(至少术前两周),不能评估长期用药效果。
- 仅纳入拟行开放修复的大AAA患者,结果外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Experimental studies suggest that fenofibrate prevents abdominal aortic aneurysm (AAA) development by lowering aortic osteopontin (OPN) concentration and reducing the number of macrophages infiltrating the aortic wall. The current study examined the effects of a short course of fenofibrate on AAA pathology in people with large AAAs awaiting aortic repair. METHODS: This randomised double blind parallel trial included male and female participants aged ≥ 60 years who had an asymptomatic AAA measuring ≥ 50 mm and were scheduled to undergo open AAA repair. Participants were allocated to fenofibrate (145 mg/day) or matching placebo for at least two weeks before elective AAA repair. Blood samples were collected at recruitment and immediately prior to surgery. AAA biopsies were obtained during aortic surgery. The primary outcomes were (1) AAA OPN concentration; (2) serum OPN concentration; and (3) number of AAA macrophages. Exploratory outcomes included circulating and aortic concentrations of other proteins previously associated with AAA. Outcomes assessed at a single time point were compared using logistic regression. Longitudinal outcomes were compared using linear mixed effects models. RESULTS: Forty-three participants were randomised. After three withdrawals, 40 were followed until the time of surgery (21 allocated fenofibrate and 19 allocated placebo). As expected, serum triglycerides reduced significantly from recruitment to the time of surgery in participants allocated fenofibrate. No differences in any of the primary and exploratory outcomes were observed between groups. CONCLUSION: A short course of 145 mg of fenofibrate/day did not lower concentrations of OPN or aortic macrophage density in people with large AAAs.
引用
- Moxon JV, Rowbotham SE, Pinchbeck JL, et al. A Randomised Controlled Trial Assessing the Effects of Peri-operative Fenofibrate Administration on Abdominal Aortic Aneurysm Pathology: Outcomes From the FAME Trial. Eur J Vasc Endovasc Surg. 2020. PMID: 32703634. doi:10.1016/j.ejvs.2020.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。